Braveheart Bio (NASDAQ:BRVE) Coverage Initiated at Stifel Nicolaus

Stifel Nicolaus started coverage on shares of Braveheart Bio (NASDAQ:BRVE) in a research note issued on Monday, Marketbeat Ratings reports. The firm set a “buy” rating and a $45.00 price target on the stock. Stifel Nicolaus’ price objective points to a potential upside of 63.99% from the company’s current price.

Other research analysts have also issued reports about the stock. TD Cowen began coverage on shares of Braveheart Bio in a research note on Monday. They issued a “buy” rating on the stock. Jefferies Financial Group initiated coverage on Braveheart Bio in a research report on Monday. They issued a “buy” rating and a $48.00 price target for the company. Wall Street Zen upgraded Braveheart Bio to a “hold” rating in a research report on Saturday, August 15th. Cantor Fitzgerald started coverage on Braveheart Bio in a research note on Monday. They set an “overweight” rating and a $40.00 price objective on the stock. Finally, The Goldman Sachs Group assumed coverage on Braveheart Bio in a report on Monday. They issued a “buy” rating and a $48.00 target price for the company. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $45.25.

Braveheart Bio Price Performance

BRVE opened at $27.44 on Monday. Braveheart Bio has a twelve month low of $24.61 and a twelve month high of $32.00.

Insider Buying and Selling at Braveheart Bio

In other news, Director David Charles Lubner purchased 55,555 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $999,990.00. Following the acquisition, the director directly owned 55,555 shares of the company’s stock, valued at approximately $999,990. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Bio Fund Iv L.P. Ah acquired 1,100,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $19,800,000.00. Following the completion of the acquisition, the insider directly owned 10,232,420 shares of the company’s stock, valued at $184,183,560. The trade was a 12.05% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 8,751,942 shares of company stock worth $157,534,956.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.